Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanes

Next Previous
Trial Profile

Evaluation of safety and efficacy of eribulin for patients advanced or recurrent HER2 negative breast cancer who have been treated with anthracyclines and taxanes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 08 Jun 2021 Results (n=45) of retrospective analysis of this trial assessing baseline neutrophil-to-lymphocyte ratio and absolute lymphocyte count, to predict progression-free survival or overall survival, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
  • 26 Jan 2012 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top